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Abstract: It has been proposed that the excess of familiar risk associated with breast cancer could be explained by the 
cumulative effect of multiple weakly predisposing alleles. The transcriptional repressor FBI1, also known as Pokemon, has 
recently been identiﬁ  ed as a critical factor in oncogenesis. This protein is encoded by the ZBTB7 gene. Here we aimed to 
determine whether polymorphisms in ZBTB7 are associated with breast cancer risk in a sample of cases and controls col-
lected in hospitals from North and Central Spanish patients. We genotyped 15 SNPs in ZBTB7, including the ﬂ  anking regions, 
with an average coverage of 1 SNP/2.4 Kb, in 360 sporadic breast cancer cases and 402 controls. Comparison of allele, 
genotype and haplotype frequencies between cases and controls did not reveal associations using Pearson’s chi-square test 
and a permutation procedure to correct for multiple test. In this, the ﬁ  rst study of the ZBTB7 gene in relation to, sporadic 
breast cancer, we found no evidence of an association.
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Introduction
It has been suggested that breast cancer, together with prostate and colorectal, are the cancers with the 
highest heritable components. A substantial proportion of familiar breast cancer (~25%) is explained 
by mutations in the BRCA1 and BRCA2 genes [1,2]. By contrast, the excess of familial risk associated 
with sporadic breast cancer (as well as the unexplained genetic risk in familial breast cancer) may be 
better explained by the effect of multiple weakly predisposing alleles [3,4]. The identiﬁ  cation of com-
mon alleles conferring modest susceptibility to cancer (as opposed to the known high penetrance 
BRCA1/2 genes) is a ﬁ  eld of growing interest, especially with the development of new genotyping 
techniques and SNP database facilities [5].
Hence, there is much interest in the search for low penetrance gene/variants for breast cancer, which 
could exist with relatively high prevalence in the general population. Many polymorphisms have been 
proposed as candidates for susceptibility to sporadic breast cancer but reported positive associations 
have rarely been replicated in independent studies [6–9].
Recently, Maeda et al. [10] identiﬁ  ed the transcriptional repressor FBI1, namely Pokemon (POK 
erythroid myeloid ontogenic factor), as a critical factor in oncogenesis. This protein is encoded by the 
ZBTB7 gene (“zing ﬁ  nger and BTB domain containing 7”; Gene ID: 51341). Mouse embyronic ﬁ  broblasts 
lacking ZBTB7 are completely refractory to oncogene-mediated cellular transformation. Conversely, 
FBI1 over-expression led to overt oncogenic transformation both in vitro and in vivo in transgenic mice. 
FBI1 can speciﬁ  cally repress the transcription of the tumor suppressor gene ARF (600160). Maeda et al. 
[10] found that FBI1 is aberrantly over-expressed in human cancers, and its expression levels predict 
biologic behaviour and clinical outcome. On the other hand, tissue microarray (TMA) analysis in breast 
carcinomas has revealed high levels of Pokemon expression in a subset of these tumours. In addition, 
the genomic region where the ZBTB7 gene resides (19p13.3) is a hotspot for chromosomal translocations 358
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(The Cancer Genome Anatomy Project; http://
cgap.nci.nih.gov/). ZBTB7 is therefore a good 
candidate low penetrance breast cancer susceptibil-
ity gene.
Here we aimed to study the potential implica-
tions of common ZBTB7 variants in sporadic breast 
cancer in a sample of cases and controls from 
Spain. To do this, we selected a set of 19 SNPs 
covering the whole extension of ZBTB7 and ﬂ  ank-
ing regions at high density.
Material and Methods
Study subjects and DNA extraction
Cases were 360 Spanish women with breast cancer 
and mean age at diagnosis of 59 years (range 25 
to 85 years), recruited between 2000 and 2004 
(48% of cases were recruited within one year of 
their diagnosis and 79% within ﬁ  ve years). All 
cases were collected from a consecutive series 
recruited via three public Spanish hospitals: Hos-
pital La Paz (20%), Fundación Jiménez Díaz 
(50%) and Hospital Monte Naranco (30%). Our 
samples contain prevalently invasive cases of 
breast cancer, 96%; while only 4% of in situ breast 
cancer. Controls were 402 Spanish women free of 
breast cancer at ages ranging from 24 to 85 years 
(mean = 53 years) and recruited between 2000 and 
2005, via the Menopause Research Centre at the 
Instituto Palacios (50%), the Colegio de Abogados 
(31%) and the Centro Nacional de Transfusiones 
(19%), all in Madrid. While data was not available 
to calculate response rates, our experience is that 
response rates are very high for cases (~90%).
Genomic DNA was isolated from peripheral 
blood lymphocytes using automatic DNA extrac-
tion (Magnapure, Roche) according to the manu-
facturer’s recommended protocols. DNA was 
quantiﬁ  ed using picogreen and diluted to a ﬁ  nal 
concentration of 50 ng/ul for genotyping. Informed 
consent was obtained from all participants and the 
study was approved by the institutional review 
boards of Hospital Clínico Universitario (Santiago 
de Compostela, Galicia, Spain) and Hospital La 
Paz, Madrid.
SNP selection
SNPs were selected from different sources: the 
International HapMap Project (The International 
HapMap Consortium, 2003; 2004; http://www.
hapmap.org/), Ensembl (Birney et al. 2004; http://
www.ensemble.org/), the Sequenom RealSNP data-
base (https://www.realsnp.com/default.asp), and 
PupaSNP (Conde et al. 2004; http://www.pupasnp.
org/). All 22 SNPs described at the time of selection 
were included, which yielded an average coverage 
of 1 SNP/1.7 Kb. These SNPs cover the upstream 
and downstream ﬂ  anking regions (10000 bp) and 
the introns of ZBTB7, and include only one coding 
non-synonymous SNPs (Table 1).
SNP genotyping
Genotyping was performed using the MassARRAY 
SNP genotyping system (Sequenom Inc., San Diego, 
CA) located at the Universidad de Santiago de Com-
postela node of the Spanish National Genotyping 
Center (Centro Nacional de Genotipado; http://www.
cegen.org), following the manufacturer’s instruc-
tions. This typing assay uses the extension of a single 
primer that binds to the sequence ﬂ  anking the muta-
tion site. Base-speciﬁ  c primer extension products are 
created 1–4 bases long depending on the substitution 
present. The different primer extension products are 
then differentiated by mass. Multiple sites 
can be typed simultaneously by multiplexing 
the extension reaction. Detection uses matrix-assisted 
laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometry with samples 
automatically genotyped from each mass spectrum 
produced. The assays were designed using Spectro 
DESIGNER software. Case and control samples 
were genotyped using 384-well plates and automated 
protocols. The allele-calling of all possible SNPs in 
each DNA sample was performed automatically 
using SpectroTYPER–RT software. Positive and 
negative controls were incorporated in each genotyp-
ing plate in order to assess genotyping quality. We 
estimate a genotyping error rate below 0.001%.
Statistical analysis
We tested for differences in allele frequencies 
between cases and controls using Pearson’s Chi-
squared test (the best model is provided in Table 2). 
We adjusted for age in categories 45, 44–49, 
50–54, 55–59, and 60 via logistic regression 
using Stata v8. Disequilibrium coefﬁ  cients (D’) 
for adjacent SNPs were calculated using Haplov-
iew v3.11 [11]. We used Gold software [12] to 
graphically summarized patterns of linkage 
disequilibrium in ZBTB7 because it is well suited 
to the analysis of dense genetic maps. Assuming a 359
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minimum allele frequency (MAF) of 3% (the aver-
age MAF of our SNP set) and a genetic effect of 
2, the a priori power to detect association under a 
dominant model is above 70%.
Haploview v3.32 (http://www.broad.mit.edu/
mpg/haploview) was used for estimating the 
genotyping coverage of the selected SNPs (see 
below) and haplotype block structure.
The Cocaphased program of the Unphased 
software package [13] was used to check for single 
SNP and haplotype associations. We tested all two-, 
three-, four-, and ﬁ  ve-SNP haplotypes for associa-
tion in a sliding window across the gene. The 
option ‘drop rare haplotypes’ was used in order to 
restrict the analysis to the haplotypes with a 
frequency 1%. We followed the permutation test 
procedure implemented in Unphased which 
provides P-values corrected for the multiple hap-
lotypes tested. The EM algorithm was used to 
impute missing data.
Evaluation of stratification was carried out 
based on the genotyping of 28 neutral SNPs, as 
previously described in a separate study that tar-
geted a different set of low penetrance breast 
cancer genes in overlapping samples [14].
Results and Discussion
Three out of the 22 SNPs selected failed genotyp-
ing. Four out of the 19 remaining SNPs (namely, 
rs10405522, rs895330, rs350840, and rs350832) 
were successfully genotyped in less than 75% of 
the samples and were therefore excluded from 
association analyses. The average call rate for 
Table 1. ZBTB7 SNPs successfully genotyped.
ID SNP Alleles MA MAF (%) Chr. 19 
location in 
Ensembl 
v.31
aa change Position 
(bp)
Intermarker 
Distance (bp)
Distance 
from v01 
(bp)
– rs10405522 C/G G 2.4 3’-down-
stream
– 3990056 – –
v1 rs11882361 A/G G 2.9 3’-down-
stream
– 3993858 3802 3802
v2 rs2121137 C/T T 2.6 3’-down-
stream
– 3993923 65 3867
v3 rs2121136 C/T T 2.6 3’-down-
stream
– 3994024 101 3968
v4 rs2121135 A/G A 0.2 3’-down-
stream
– 3994038 14 3982
v5 rs10414035 A/G G 0.3 3’-down-
stream
– 3996434 2396 6378
v6 rs10412825 A/G A 0.1 3’-down-
stream
– 3996962 528 6906
v7 rs4807540 C/T T 4.0 intronic – 4001399 4437 11343
v8 rs7251080 C/T T 0.8 coding 341syn 4005208 3809 15152
v9 rs3745985 C/T T 0.3 coding A177T 4005702 494 15646
v10 rs10409301 C/T T 4.7 intronic – 4007346 1644 17290
v11 rs895331 G/T G 2.1 intronic – 4011222 3876 21166
– rs895330 C/G C 22.7 intronic – 4011707 485 21651
v12 rs350842 C/T C 1.1 intronic – 4012781 1074 22725
v13 rs350841 A/G A 0.9 intronic – 4014067 1286 24011
– rs350840 C/G C 1.9 intronic – 4015418 1351 25362
v14 rs1992710 C/G C 0.2 intronic – 4015672 254 25616
– rs350832 C/T C 22.9 5’-upstream – 4020426 4754 30370
v15 rs11880023 C/T T 21.1 5’-upstream – 4025697 5271 35641
Abbreviations: MA: minor allele; MAF: control minor allele frequency; aa: aminoacid.360
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Figure 1. D’ pairwise linkage disequilibrium values of ZBTB7 markers in control individuals.
Table 2. OR and P-value for the best ﬁ  tting model.
SNP Rare Allele Best Model OR
1 95% CI Un-adjusted 
P-value
rs11882361 G Dom.
2 1.30 0.70–2.42 0.4
rs2121137 A Dom.
2 1.32 0.69–2.53 0.4
rs2121136 T Dom.
2 1.36 0.69–2.68 0.4
rs2121135 T Dom.
2 0.54 0.05–5.96 0.6
rs10414035 G Dom.
2 2.18 0.20–24.1 0.5
rs10412825 A Dom.
2 1.11 0.07–17.7 0.9
rs4807540 T Dom.
2 0.95 0.54–1.70 0.9
rs7251080 T Dom.
2 1.91 0.51–7.18 0.3
rs3745985 T Dom.
2 1.08 0.15–7.71 0.9
rs10409301 T Rec. 0.27 0.06–1.29 0.1
rs895331 C Dom.
2 0.99 0.48–2.06 0.9
rs350842 C Dom.
2 0.70 0.24–2.08 0.5
rs350841 A Dom. 0.78 0.24–2.47 0.7
rs1992710 C Dom.
2 0.52 0.05–5.81 0.6
rs11880023 T Rec. 0.69 0.32–1.48 0.3
1Using common-allele homozygotes as reference. The P-value refers to a Pearson’s Chi-squared test.
2Only model that could be ﬁ  t due to zero counts for rare homozygotes.361
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these 15 SNPs was 95% (see also preliminary 
results in [15–17]) and none gave evidence 
of deviation from Hardy Weinberg equilibrium. 
Table 1 summarizes their location and allele 
frequencies.
We computed D’ values between all 19 markers, 
and detected moderate levels of LD (Fig. 1). How-
ever, under the ‘four gamete rule’ model (see 
Haploview for more information) we identiﬁ  ed a 
haplotype blocks nearly covering the entire exten-
sion of the gene (Fig. 2). This characterization of 
LD along the ZTBT7 region could be useful for 
future association study designs in cancer.
In order to measure the percentage of variability 
captured by the our selected SNPs, we first 
collected the HapMap data from the CEPH subset 
(http://www.hapmap.org) and the same chromosome 
range explored in the present study (chromosome 
19: positions 3990056–4025697). Then, we esti-
mated the number of SNPs un-captured in the 
CEPH-HapMap using our SNP selection under an 
r
2 threshold of 0.8 and a model of ‘aggressive tag-
ging’. Only one SNP in the HapMap dataset would 
remain untagged by our selected SNPs, indicating 
that our set of SNPs covers well the whole gene 
region under analysis.
Figure 2. Haplotype block structure in our control individuals and HapMap information for the CEPH dataset (top).362
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No statistically signiﬁ  cant differences between 
cases and controls were observed for individual 
SNPs based on comparisons of allele frequencies 
(see Table 2 for the best ﬁ  tting models) whether or 
not age was adjusted for. Four- and three-SNPs 
haplotypes carrying markers rs350842 and rs350841 
had associated P-values below 0.05 but were not 
signiﬁ  cant after correction for multiple testing. Note 
also that these adjusted P-values overestimates the 
real value since the software employed (cocaphase) 
does not correct for the multiple hypothesis tested 
running different sliding windows.
To our knowledge, this is the ﬁ  rst time that 
ZBTB7 has been evaluated as a candidate sporadic 
breast cancer susceptibility gene. We have not 
found evidence of an association for ZBTB7 SNPs 
nor haplotypes with breast cancer risk. It should 
be mentioned that most of the ZBTB7 variants 
studied are rare in our sample. We are aware that 
the main drawback in detecting positive associa-
tions of rare variants (or haplotypes) is the need 
for large sample sizes. Therefore, the present result 
needs further validation in future studies of inde-
pendent case-control series before a role for ZBTB7 
in breast cancer can be completely ruled out.
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